Literature DB >> 23394808

von Willebrand factor and cancer: a renewed interest.

Massimo Franchini1, Francesco Frattini, Silvia Crestani, Carlo Bonfanti, Giuseppe Lippi.   

Abstract

Von Willebrand factor (VWF), the largest human plasma protein, is an adhesive multimeric glycoprotein that mediates platelet adhesion to both the subendothelial matrix and endothelial surfaces and acts as a carrier for coagulation factor VIII in the circulation. Besides its essential role in hemostasis, there is growing evidence from the literature that VWF has an additional antitumor effect, mainly by exerting negative modulation on angiogenesis and apoptosis. Current knowledge on the link between VWF and cancer is summarized in this review, based on an analysis of the most important experimental and clinical studies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394808     DOI: 10.1016/j.thromres.2013.01.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  36 in total

1.  The endothelial glycocalyx anchors von Willebrand factor fibers to the vascular endothelium.

Authors:  Thejaswi Kalagara; Tracy Moutsis; Yi Yang; Karin I Pappelbaum; Anne Farken; Lucia Cladder-Micus; Sabine Vidal-Y-Sy; Axel John; Alexander T Bauer; Bruno M Moerschbacher; Stefan W Schneider; Christian Gorzelanny
Journal:  Blood Adv       Date:  2018-09-25

2.  ABO blood groups in relation to breast carcinoma incidence and associated prognostic factors in Moroccan women.

Authors:  S Zouine; F Marnissi; N Otmani; M Bennani Othmani; M El Wafi; K Kojok; Y Zaid; N Tahiri Jouti; N Habti
Journal:  Med Oncol       Date:  2016-05-30       Impact factor: 3.064

3.  ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.

Authors:  Donatas Stakišaitis; Milda Juknevičienė; Albertas Ulys; Dalia Žaliūnienė; Daiva Stanislovaitienė; Ramunė Šepetienė; Anželika Slavinska; Kęstutis Sužiedėlis; Vita Lesauskaitė
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

4.  Glioblastoma and ABO blood groups: further evidence of an association between the distribution of blood group antigens and brain tumours.

Authors:  Mohammed Z Allouh; Mohammed M Al Barbarawi; Mohammad Y Hiasat; Mohammed A Al-Qaralleh; Emad I Ababneh
Journal:  Blood Transfus       Date:  2016-06-30       Impact factor: 3.443

5.  High relative density of lymphatic vessels predicts poor survival in tongue squamous cell carcinoma.

Authors:  Miia Seppälä; Konsta Pohjola; Jussi Laranne; Markus Rautiainen; Heini Huhtala; Risto Renkonen; Karl Lemström; Timo Paavonen; Sanna Toppila-Salmi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-06-21       Impact factor: 2.503

6.  A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.

Authors:  Andrea Pace; Chiara Mandoj; Anna Antenucci; Veronica Villani; Isabella Sperduti; Beatrice Casini; Mariantonia Carosi; Alessandra Fabi; Antonello Vidiri; Tatiana Koudriavtseva; Laura Conti
Journal:  J Neurooncol       Date:  2018-03-28       Impact factor: 4.130

7.  Increased von Willebrand factor over decreased ADAMTS-13 activity is associated with poor prognosis in patients with advanced non-small-cell lung cancer.

Authors:  Renyong Guo; Jiezuan Yang; Xia Liu; Jianping Wu; Yu Chen
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

8.  Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.

Authors:  Michal Reichert
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

9.  Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival.

Authors:  Danwen Qian; Hongliang Liu; Xiaomeng Wang; Jie Ge; Sheng Luo; Edward F Patz; Patricia G Moorman; Li Su; Sipeng Shen; David C Christiani; Qingyi Wei
Journal:  Int J Cancer       Date:  2018-12-08       Impact factor: 7.396

Review 10.  The prognostic value of ABO blood group in cancer patients.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.